Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 6/2009

01-12-2009 | Review

Treatment of Lyme borreliosis

Authors: Hermann J Girschick, Henner Morbach, Dennis Tappe

Published in: Arthritis Research & Therapy | Issue 6/2009

Login to get access

Abstract

Borrelia burgdorferi sensu lato is the causative agent of Lyme borreliosis in humans. This inflammatory disease can affect the skin, the peripheral and central nervous system, the musculoskeletal and cardiovascular system and rarely the eyes. Early stages are directly associated with viable bacteria at the site of inflammation. The pathogen-host interaction is complex and has been elucidated only in part. B. burgdorferi is highly susceptible to antibiotic treatment and the majority of patients profit from this treatment. Some patients develop chronic persistent disease despite repeated antibiotics. Whether this is a sequel of pathogen persistence or a status of chronic auto-inflammation, auto-immunity or a form of fibromyalgia is highly debated. Since vaccination is not available, prevention of a tick bite or chemoprophylaxis is important. If the infection is manifest, then treatment strategies should target not only the pathogen by using antibiotics but also the chronic inflammation by using anti-inflammatory drugs.
Appendix
Available only for authorised users
Literature
1.
2.
Singh SK, Girschick HJ: Lyme borreliosis: from infection to autoimmunity. Clin Microbiol Infect. 2004, 10: 598-614.CrossRefPubMed
3.
Hengge UR, Tannapfel A, Tyring SK, Erbel R, Arendt G, Ruzicka T: Lyme borreliosis. Lancet Infect Dis. 2003, 3: 489-500.CrossRefPubMed
4.
5.
Herzberger P, Siegel C, Skerka C, Fingerle V, Schulte-Spechtel U, van Dam A, Wilske B, Brade V, Zipfel PF, Wallich R, Kraiczy P: Human pathogenic Borrelia spielmanii sp. nov. resists complement-mediated killing by direct binding of immune regulators factor H and factor H-like protein 1. Infect Immun. 2007, 75: 4817-4825.PubMedCentralCrossRefPubMed
6.
Stanek G, Strle F: Lyme disease: European perspective. Infect Dis Clin North Am. 2008, 22: 327-339. vii.CrossRefPubMed
7.
Gerber MA, Shapiro ED, Burke GS, Parcells VJ, Bell GL: Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. N Engl J Med. 1996, 335: 1270-1274.CrossRefPubMed
8.
Manzoor K, Aftab W, Choksi S, Khan IA: Lyme carditis: sequential electrocardiographic changes in response to antibiotic therapy. Int J Cardiol. 2009, 137: 167-171.CrossRefPubMed
9.
Huppertz HI, Girschick HJ: Lyme borreliosis. Pediatrics in systemic autoimmune diseases. 2003, Amsterdam: Elsevier BV, 6:
10.
Huppertz HI, Bohme M, Standaert SM, Karch H, Plotkin SA: Incidence of Lyme borreliosis in the Wurzburg region of Germany. Eur J Clin Microbiol Infect Dis. 1999, 18: 697-703.CrossRefPubMed
11.
Steere AC, Angelis SM: Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum. 2006, 54: 3079-3086.CrossRefPubMed
12.
Latsch K, Tappe D, Warmuth-Metz M, Hebestreit H: Central nervous system borreliosis mimicking a pontine tumour. J Med Microbiol. 2006, 55 (Pt 11): 1597-1599.CrossRefPubMed
13.
14.
Steere AC, Duray PH, Butcher EC: Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis. Comparison with rheumatoid synovium and tonsillar lymphoid tissue. Arthritis Rheum. 1988, 31: 487-495.CrossRefPubMed
15.
Singh SK, Girschick HJ: Tick-host interactions and their immunological implications in tick-borne diseases. Curr Sci. 2003, 85: 1284-1298.
16.
17.
Priem S, Burmester GR, Kamradt T, Wolbart K, Rittig MG, Krause A: Detection of Borrelia burgdorferi by polymerase chain reaction in synovial membrane, but not in synovial fluid from patients with persisting Lyme arthritis after antibiotic therapy. Ann Rheum Dis. 1998, 57: 118-121.PubMedCentralCrossRefPubMed
18.
Honegr K, Hulinska D, Dostal V, Gebousky P, Hankova E, Horacek J, Vyslouzil L, Havlasova J: Persistence of Borrelia burgdorferi sensu lato in patients with Lyme borreliosis. Epidemiol Mikrobiol Imunol. 2001, 50: 10-16.PubMed
19.
Gross D, Huber BT, Steere AC: Molecular mimicry and Lyme arthritis. Curr Dir Autoimmun. 2001, 3: 94-111.CrossRefPubMed
20.
Drouin EE, Glickstein LJ, Steere AC: Molecular characterization of the OspA(161-175) T cell epitope associated with treatment-resistant Lyme arthritis: differences among the three pathogenic species of Borrelia burgdorferi sensu lato. J Autoimmun. 2004, 23: 281-292.CrossRefPubMed
21.
Drouin EE, Glickstein L, Kwok WW, Nepom GT, Steere AC: Searching for borrelial T cell epitopes associated with antibiotic-refractory Lyme arthritis. Mol Immunol. 2008, 45: 2323-2332.PubMedCentralCrossRefPubMed
22.
Reimers CD, Neubert U, Kristoferitsch W, Pfluger KH, Mayr WR: Borrelia burgdorferi infection in Europe: an HLA-related disease?. Infection. 1992, 20: 197-200.CrossRefPubMed
23.
Huppertz HI, Karch H, Suschke HJ, Doring E, Ganser G, Thon A, Bentas W: Lyme arthritis in European children and adolescents. The Pediatric Rheumatology Collaborative Group. Arthritis Rheum. 1995, 38: 361-368.CrossRefPubMed
24.
Singh SK, Girschick HJ: Toll-like receptors in Borrelia burgdorferi-induced inflammation. Clin Microbiol Infect. 2006, 12: 705-717.CrossRefPubMed
25.
Singh SK, Girschick HJ: Molecular survival strategies of the Lyme disease spirochete Borrelia burgdorferi. Lancet Infect Dis. 2004, 4: 575-583.CrossRefPubMed
26.
Girschick HJ, Huppertz HI, Russmann H, Krenn V, Karch H: Intracellular persistence of Borrelia burgdorferi in human synovial cells. Rheumatol Int. 1996, 16: 125-132.CrossRefPubMed
27.
Haupl T, Hahn G, Rittig M, Krause A, Schoerner C, Schonherr U, Kalden JR, Burmester GR: Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis. Arthritis Rheum. 1993, 36: 1621-1626.CrossRefPubMed
28.
Honegr K, Hulinska D, Beran J, Dostal V, Havlasova J, Cermakova Z: Long term and repeated electron microscopy and PCR detection of Borrelia burgdorferi sensu lato after an antibiotic treatment. Cent Eur J Public Health. 2004, 12: 6-11.PubMed
29.
Ballantyne C: The chronic debate over Lyme disease. Nat Med. 2008, 14: 1135-1139.CrossRef
30.
Alban PS, Johnson PW, Nelson DR: Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology. 2000, 146 (Pt 1): 119-127.CrossRefPubMed
31.
Miklossy J, Kasas S, Zurn AD, McCall S, Yu S, McGeer PL: Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J Neuroinflammation. 2008, 5: 40-PubMedCentralCrossRefPubMed
32.
Wormser GP, Dattwyler RJ, Shapiro ED, Dumler JS, O'Connell S, Radolf JD, Nadelman RB: Single-dose prophylaxis against Lyme disease. Lancet Infect Dis. 2007, 7: 371-373.CrossRefPubMed
33.
34.
Steere AC, Malawista SE, Newman JH, Spieler PN, Bartenhagen NH: Antibiotic therapy in Lyme disease. Ann Intern Med. 1980, 93: 1-8.CrossRefPubMed
35.
36.
Wormser GP, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, Visintainer P, Dornbush R, Singh B, Nadelman RB: Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003, 138: 697-704.CrossRefPubMed
37.
Luger SW, Paparone P, Wormser GP, Nadelman RB, Grunwaldt E, Gomez G, Wisniewski M, Collins JJ: Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother. 1995, 39: 661-667.PubMedCentralCrossRefPubMed
38.
Massarotti EM, Luger SW, Rahn DW, Messner RP, Wong JB, Johnson RC, Steere AC: Treatment of early Lyme disease. Am J Med. 1992, 92: 396-403.CrossRefPubMed
39.
Luft BJ, Dattwyler RJ, Johnson RC, Luger SW, Bosler EM, Rahn DW, Masters EJ, Grunwaldt E, Gadgil SD: Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med. 1996, 124: 785-791.CrossRefPubMed
40.
41.
Dattwyler RJ, Luft BJ, Kunkel MJ, Finkel MF, Wormser GP, Rush TJ, Grunwaldt E, Agger WA, Franklin M, Oswald D, Cockey L, Maladorno D: Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med. 1997, 337: 289-294.CrossRefPubMed
42.
Eppes SC, Childs JA: Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics. 2002, 109: 1173-1177.CrossRefPubMed
43.
Arnez M, Pleterski-Rigler D, Luznik-Bufon T, Ruzic-Sabljic E, Strle F: Solitary erythema migrans in children: comparison of treatment with azithromycin and phenoxymethylpenicillin. Wien Klin Wochenschr. 2002, 114: 498-504.PubMed
44.
Krause PJ, Telford SR, Spielman A, Sikand V, Ryan R, Christianson D, Burke G, Brassard P, Pollack R, Peck J, Persing DH: Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness. JAMA. 1996, 275: 1657-1660.CrossRefPubMed
45.
Hilton E, DeVoti J, Benach JL, Halluska ML, White DJ, Paxton H, Dumler JS: Seroprevalence and seroconversion for tick-borne diseases in a high-risk population in the northeast United States. Am J Med. 1999, 106: 404-409.CrossRefPubMed
46.
47.
Sood SK: What we have learned about Lyme borreliosis from studies in children. Wien Klin Wochenschr. 2006, 118: 638-642.CrossRefPubMed
48.
Halperin JJ: Diagnosis and treatment of the neuromuscular manifestations of lyme disease. Curr Treat Options Neurol. 2007, 9: 93-100.CrossRefPubMed
49.
Tveitnes D, Oymar K, Natas O: Laboratory data in children with Lyme neuroborreliosis, relation to clinical presentation and duration of symptoms. Scand J Infect Dis. 2009, 41: 355-362.CrossRefPubMed
50.
Tiemstra JD, Khatkhate N: Bell's palsy: diagnosis and management. Am Fam Physician. 2007, 76: 997-1002.PubMed
51.
Wilke M, Eiffert H, Christen HJ, Hanefeld F: Primarily chronic and cerebrovascular course of Lyme neuroborreliosis: case reports and literature review. Arch Dis Child. 2000, 83: 67-71.PubMedCentralCrossRefPubMed
52.
Szer IS, Taylor E, Steere AC: The long-term course of Lyme arthritis in children. N Engl J Med. 1991, 325: 159-163.CrossRefPubMed
53.
Kannian P, Drouin EE, Glickstein L, Kwok WW, Nepom GT, Steere AC: Decline in the frequencies of Borrelia burgdorferi OspA161 175-specific T cells after antibiotic therapy in HLA-DRB1*0401-positive patients with antibiotic-responsive or antibiotic-refractory lyme arthritis. J Immunol. 2007, 179: 6336-6342.CrossRefPubMed
54.
Dressler F, Girschick HJ, Huppertz HI, Lahdenne P: Pediatric Rheumatology European Society Clinical Guidelines: Lyme arthritis. Pediatr Rheumatol Online J. 2004, 8: 346-349.
55.
Luft BJ, Bosler EM, Dattwyler RJ: Lyme borreliosis. Int J Antimicrobial Agents. 1994, 3: 251-258.CrossRef
56.
Bentas W, Karch H, Huppertz HI: Lyme arthritis in children and adolescents: outcome 12 months after initiation of antibiotic therapy. J Rheumatol. 2000, 27: 2025-2030.PubMed
57.
Logigian EL, Kaplan RF, Steere AC: Chronic neurologic manifestations of Lyme disease. N Engl J Med. 1990, 323: 1438-1444.CrossRefPubMed
58.
Lopez-Alberola RF: Neuroborreliosis and the pediatric population: a review. Rev Neurol. 2006, 42 (Suppl 3): S91-S96.PubMed
59.
Asbrink E, Hovmark A, Hederstedt B: The spirochetal etiology of acrodermatitis chronica atrophicans Herxheimer. Acta Derm Venereol. 1984, 64: 506-512.PubMed
60.
Mullegger RR, Glatz M: Skin manifestations of lyme borreliosis: diagnosis and management. Am J Clin Dermatol. 2008, 9: 355-368.CrossRefPubMed
61.
Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall D, McCall J, Kosinski M, Weinstein A: Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001, 345: 85-92.CrossRefPubMed
62.
Feder HM, Johnson BJ, O'Connell S, Shapiro ED, Steere AC, Wormser GP: A critical appraisal of 'chronic Lyme disease'. N Engl J Med. 2007, 357: 1422-1430.CrossRefPubMed
63.
Seidel MF, Domene AB, Vetter H: Differential diagnoses of suspected Lyme borreliosis or post-Lyme-disease syndrome. Eur J Clin Microbiol Infect Dis. 2007, 26: 611-617.CrossRefPubMed
64.
65.
Holl-Wieden A, Suerbaum S, Girschick HJ: Seronegative Lyme arthritis. Rheumatol Int. 2007, 27: 1091-1093.CrossRefPubMed
66.
Schutzer SE, Coyle PK, Reid P, Holland B: Borrelia burgdorferi-specific immune complexes in acute Lyme disease. JAMA. 1999, 282: 1942-1946.CrossRefPubMed
67.
Fawcett PT, Rose CD, Gibney KM, Doughty RA: Correlation of seroreactivity with response to antibiotics in pediatric Lyme borreliosis. Clin Diagn Lab Immunol. 1997, 4: 85-88.PubMedCentralPubMed
68.
Stricker RB, Lautin A, Burrascano JJ: Lyme disease: the quest for magic bullets. Chemotherapy. 2006, 52: 53-59.CrossRefPubMed
69.
Hovius JW, van Dam AP, Fikrig E: Tick-host-pathogen interactions in Lyme borreliosis. Trends Parasitol. 2007, 23: 434-438.CrossRefPubMed
70.
Simon MM, Schaible UE, Wallich R, Kramer MD: A mouse model for Borrelia burgdorferi infection: approach to a vaccine against Lyme disease. Immunol Today. 1991, 12: 11-16.CrossRefPubMed
71.
Sikand VK, Halsey N, Krause PJ, Sood SK, Geller R, Van Hoecke C, Buscarino C, Parenti D: Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial. Pediatrics. 2001, 108: 123-128.CrossRefPubMed
72.
Telford SR, Fikrig E, Barthold SW, Brunet LR, Spielman A, Flavell RA: Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines. J Exp Med. 1993, 178: 755-758.CrossRefPubMed
73.
de Silva AM, Telford SR, Brunet LR, Barthold SW, Fikrig E: Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J Exp Med. 1996, 183: 271-275.CrossRefPubMed
74.
Hsia EC, Chung JB, Schwartz JS, Albert DA: Cost-effectiveness analysis of the Lyme disease vaccine. Arthritis Rheum. 2002, 46: 1651-1660.CrossRefPubMed
Metadata
Title
Treatment of Lyme borreliosis
Authors
Hermann J Girschick
Henner Morbach
Dennis Tappe
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 6/2009
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2853

Other articles of this Issue 6/2009

Arthritis Research & Therapy 6/2009 Go to the issue

Research article

Comparative, double-blind, controlled study of intra-articular hyaluronic acid (Hyalubrix®) injections versus local anesthetic in osteoarthritis of the hip

Editorial

SAPHO syndrome: Is a range of pathogen-associated rheumatic diseases extended?

Research article

Altered peptide ligands inhibit arthritis induced by glucose-6-phosphate isomerase peptide

Editorial

TWEAK: a novel biomarker for lupus nephritis?

Research article

Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment

Review

Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits